SOTHEMACAS:SOT 75 Net Margin % is 11.44% as of Dec. 2025, which is 3% below its 10-year median of 11.77. GuruFocus rates CAS:SOT with a GF Score™ of 75/100 and a GF Value™ of MAD284.83 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 956 Drug Manufacturers companies, SOTHEMA ranks better than 70.5% on this metric.
Net margin is calculated as Net Income divided by its Revenue. SOTHEMA's Net Income for the
six
months ended in Dec. 2025 was MAD192 Mil. SOTHEMA's Revenue for the
six
months ended in Dec. 2025 was MAD1,676 Mil. Therefore, SOTHEMA's net margin for the quarter that ended in Dec. 2025 was 11.44%.
The historical rank and industry rank for SOTHEMA's Net Margin % or its related term are showing as below:
CAS:SOT'
s Net Margin % Range Over the Past 10 Years
Min: 10.57 Med: 11.77 Max: 13.66
Current: 11.95
CAS:SOT's Net Margin % is ranked better than 70.5% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs CAS:SOT: 11.95
SOTHEMA (CAS:SOT) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
SOTHEMA Net Margin % Related Terms
SOTHEMA Net Margin % Historical Data
* Premium members only.
The historical data trend for SOTHEMA's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAS:SOT vs LLY, JNJ, ABBV: Net Margin % Comparison
For the Drug Manufacturers - General subindustry, SOTHEMA's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SOTHEMA Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SOTHEMA's Net Margin % distribution charts can be found below:
* The bar in red indicates where SOTHEMA's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SOTHEMA (CAS:SOT) has a Net Margin % of 11.44% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on SOTHEMA and its competitors. This is near median its historical median of 11.77. Over the past decade, SOTHEMA's Net Margin % has ranged from 10.57 to 13.66. According to the industry distribution chart, SOTHEMA ranks #282 out of 956 companies in the Drug Manufacturers industry, placing it in the top 29.5%.
Is SOTHEMA's Net Margin % too high?
SOTHEMA's current Net Margin % of 11.44% is near median its 10-year median of 11.77. Over the past 10 years, this metric has ranged from a low of 10.57 to a high of 13.66. The Drug Manufacturers industry median Net Margin % is 5.56. SOTHEMA's value of 11.44% is 105.8% above this industry median. Based on the distribution chart, SOTHEMA ranks #282 out of 956 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, SOTHEMA has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SOTHEMA's Net Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, SOTHEMA ranks #282 out of 956 companies for Net Margin %. This puts SOTHEMA in the upper half of its industry. The industry median Net Margin % is 5.56. SOTHEMA's value of 11.44% is 105.8% above this benchmark. Historically, SOTHEMA's own Net Margin % has ranged from 10.57 to 13.66 over the past decade. While the company's 10-year median is 11.77 vs. the industry median of 5.56, SOTHEMA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SOTHEMA's current Net Margin % of 11.44% is 105.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on SOTHEMA and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SOTHEMA's current Net Margin % is 11.44%, which is near median its own 10-year median of 11.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SOTHEMA stock overvalued right now?
Based on GuruFocus' analysis, SOTHEMA (CAS:SOT) is currently considered Significantly Overvalued. The stock's GF Value™ is MAD284.83, compared to a current price of MAD376.00 — trading 32% above its estimated fair value. The current Net Margin % is 11.44%, which is near median its 10-year median of 11.77 and 105.8% above the Drug Manufacturers industry median of 5.56. SOTHEMA's overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For SOTHEMA (CAS:SOT), the current Net Margin % is 11.44% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SOTHEMA (CAS:SOT) Overvalued in 2026?
Based on GuruFocus' analysis, SOTHEMA stock appears to be overvalued.
The current stock price of MAD376.00 is trading 32% above its estimated GF Value™ of MAD284.83.
GuruFocus considers SOTHEMA to be Significantly Overvalued.
Key valuation signals for CAS:SOT:
Net Margin %: 11.44% (near median its 10-year median of 11.77)
GF Value™: MAD284.83 vs. price of MAD376.00 (32% above fair value)
Industry Position: 105.8% above the Drug Manufacturers median (#282 of 956)
No single metric tells the full story. See the CAS:SOT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SOTHEMA engages in representation, purchase and sale of pharmaceutical, chemical, health-related, biological, veterinary, plant-based, cosmetic and scented products. The company sells its products in Morocco and overseas.
75GF Score
Get the complete analysis for CAS:SOT
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAS:SOT has been successfully added to your 
